Delivery Order SPE2DB25D9365-SPE2DB25FUJPD

Award Date 5/1/25
Potential Completion Date 5/22/25
Potential Value $6.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $51,366.90 contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with an ultimate completion date of October 21, 2024. DMS Pharmaceutical Group holds a $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue firm...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,848.88 contract is for the delivery of XOLAIR 150 MG/ML AUTOINJECTORML, a specialty pharmaceutical product, with a period of performance through August 19, 2024. This delivery order is placed against DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC)...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $3,424.44 and has a period of performance through July 23, 2024. The contract is for the delivery of XOLAIR 150 MG/ML AUTOINJECTORML, a specialty pharmaceutical product. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 indefinite delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,424.46 firm fixed-price contract is for the supply of 4566380230 - XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a specialized pharmaceutical product. The contract has a period of performance through November 27, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,424.46 contract is for the delivery of 4566894752 - XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a completion date of January 30, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $6,848.92, is for the delivery of 4,567,977,335 units of the pharmaceutical product XOLAIR 300 MG/2 ML AUTOINJECT 2ML. The contract has an ultimate completion date of April 29, 2025. DMS Pharmaceutical Group Inc. is the prime contractor, and there are no major subcontractors mentioned. This contract is part of the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has a ceiling value of $5,136.69 and covers the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML pharmaceutical products. The contract has a period of performance through May 1, 2025. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a ceiling value of $3,424.46 and a period of performance through May 9, 2025. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $6,848.92, is for the delivery of 4,567,991,918 units of the pharmaceutical product XOLAIR 300 MG/2 ML AUTOINJECT 2ML. The contract has an ultimate completion date of May 7, 2025. DMS Pharmaceutical Group Inc. is a crucial supplier in the federal pharmaceutical supply chain, holding a significant single-award Indefinite...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a ceiling value of $5,136.69 and a completion date of May 8, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm...
  • SPE2DB25D9365
    Indefinite Delivery Contract
  • SPE2DB25D9365-SPE2DB25FUJPD
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $6,848.92, is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product. The contract has an ultimate completion date of May 22, 2025. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to issue delivery orders for a range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. This contract was awarded without any set-aside designation.

Generated 7/31/25, 9:43 AM